TNYA Tenaya Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1858848 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.0%
TTM EPS YoY36.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-148.2%
ROA-112.1%
ROIC (approx.)-1,156.6%
Asset turnover—
Leverage & solvency
Liabilities / assets28.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-52.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.70M | $1.11M | $225,000 | — | — | $0 | $0 | — |
| R&D expense | $14.87M | $16.60M | $14.84M | $14.80M | $15.36M | $17.37M | $21.08M | $18.69M |
| SG&A expense | $5.65M | $5.41M | $5.45M | $5.98M | $5.57M | $6.71M | $6.46M | $5.96M |
| Operating income | -$19.57M | -$44.09M | -$20.07M | -$20.77M | -$20.94M | -$24.08M | -$27.54M | -$24.65M |
| Pretax income | -$18.94M | -$43.39M | -$19.27M | -$20.18M | -$20.27M | -$23.28M | -$26.86M | -$23.84M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.94M | -$43.39M | -$19.27M | -$20.18M | -$20.27M | -$23.28M | -$26.86M | -$23.84M |
| EBITDA | -$19.17M | -$42.39M | -$18.30M | -$18.95M | -$19.04M | -$21.98M | -$24.88M | -$22.56M |
| EPS (basic) | -0.08 | -0.20 | -0.09 | — | -0.12 | -0.14 | -0.24 | — |
| EPS (diluted) | -0.08 | -0.20 | -0.09 | — | -0.12 | -0.14 | -0.24 | — |
| Weighted avg. shares (diluted) | 226.01M | 217.57M | 216.88M | — | 163.35M | 162.79M | 109.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $66.80M | $78.08M | $80.89M | $100.55M | $56.31M | $62.67M | $53.77M | $4.32M |
| Short-term investments | — | — | — | — | — | $9.00M | $34.39M | $57.12M |
| Receivables | $573,000 | $371,000 | $10.63M | — | — | — | — | — |
| Current assets | $71.01M | $86.01M | $96.56M | $105.59M | $61.24M | $75.88M | $94.48M | $67.38M |
| PP&E, net | $1.14M | $2.49M | $25.96M | $27.67M | $29.44M | $31.29M | $33.36M | $35.86M |
| Total assets | $76.68M | $93.54M | $135.07M | $146.92M | $104.98M | $122.15M | $143.95M | $119.94M |
| Current liabilities | $18.80M | $19.02M | $16.78M | $15.44M | $13.21M | $12.65M | $14.15M | $15.97M |
| Total liabilities | $22.16M | $24.13M | $28.88M | $23.66M | $22.11M | $22.32M | $24.56M | $27.09M |
| Shareholders' equity | $54.52M | $69.41M | $106.19M | $123.27M | $82.87M | $99.83M | $119.40M | $92.85M |
| Shares outstanding | 227.93M | 224.23M | 217.00M | 216.76M | — | — | — | 86.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.68M | -$3.55M | -$19.23M | -$13.94M | -$15.60M | -$15.61M | -$23.11M | -$18.39M |
| Capital expenditure | $0 | $159,000 | $11,000 | $67,000 | $26,000 | $142,000 | $383,000 | $204,000 |
| Free cash flow | -$17.68M | -$3.71M | -$19.25M | -$14.01M | -$15.62M | -$15.76M | -$23.50M | -$18.59M |
| Investing cash flow | $26,000 | -$159,000 | -$11,000 | -$67,000 | $8.86M | $24.99M | $22.30M | $14.10M |
| Financing cash flow | $6.37M | $909,000 | -$415,000 | $58.24M | $380,000 | -$476,000 | $50.26M | $377,000 |
| Depreciation & amortization | $400,000 | $1.70M | $1.76M | $1.83M | $1.90M | $2.10M | $2.66M | $2.09M |
| Stock-based compensation | $1.68M | $1.70M | $2.20M | $2.75M | $2.93M | $3.63M | $3.63M | $3.76M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.